

Is Big Pharma's Antidote to the COVID-19 Waiver a Viable Alternative?

July 29, 2021

ATTORNEYS

Landmon, Chad

Alex Baldwin

Life Sciences IP Review

PRACTICE AREAS

Intellectual Property

Axinn partner Chad Landmon was quoted in the *Life Sciences IP Review* article, "Is Big Pharma's Antidote to the COVID-19 Waiver a Viable Alternative?"

[Click here](#) to access the article. A subscription is required.